Recombinant monoclonal antibodies: Versatile tools for research, diagnostics, and disease therapy

The development of hybridoma technology in 1975 ushered in a new era of basic research, diagnostic, and therapeutic possibilities. Since then, monoclonal antibody technology has evolved to leverage the unique properties of the immune systems of different species and to incorporate other biotechnological advances, most notably recombinant DNA technology.

In this expert-led webinar, recombinant DNA technology and its use for the development of recombinant monoclonal antibodies will be discussed. We compare hybridoma-derived antibodies and recombinant monoclonal antibodies to clearly demonstrate the advantages that recombinant monoclonal antibodies can offer the antibody developer, manufacturer, and end user. Plus, discover the unique antibody formats that can be produced using this technology.

Key learning objectives

• How recombinant DNA technology has been applied to monoclonal antibody development
• Comparison and benefits of recombinant monoclonal antibodies over hybridoma-derived antibodies
• The antibody format options uniquely available through recombinant DNA technology

Who should attend?

• Scientists working with antibodies in research and development
• Professionals sourcing custom monoclonal antibodies as critical product components

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.